Sulbutiamine Dosage Guide: Protocols, Calculator & Safety

Starter protocol (first 4-6 weeks): 200 mg twice daily, with a choline source.

This protocol is designed for users with no prior sulbutiamine experience who want to assess tolerance and baseline response at conservative doses.

Prerequisites before starting:

1. Confirm you have exhausted basic fatigue evaluation: adequate sleep (7-9 hours), reasonable nutrition, regular exercise, management of significant stressors, and ideally basic labs including CBC, CMP, TSH, vitamin D, B12, ferritin, and fasting glucose within the last 12 months. Addressable causes of fatigue should be addressed before reaching for nootropics.
2. Confirm you are not in an active manic/hypomanic episode or acute psychiatric decompensation.
3. Confirm you are not pregnant, trying to conceive, or breastfeeding.
4. Source from a reputable vendor — prescription Arcalion from a European pharmacy, or a research-chemical vendor with third-party certificate of analysis.

Dosing:

• Sulbutiamine 200 mg with breakfast, and 200 mg with lunch. Total: 400 mg/day.
• Take with food to minimise GI upset.
• Avoid evening dosing — last dose should be no later than 2-3 PM.
• Choline co-administration: alpha-GPC 300 mg OR CDP-choline 250 mg with the morning dose. This addresses cholinergic synergy and may help reduce mild headaches in sensitive users.

Duration and assessment:

• Week 1: single morning dose (200 mg) to assess tolerance. Track energy, mood, sleep, GI symptoms, headaches.
• Weeks 2-4: 200 mg twice daily if week 1 was well tolerated.
• Weeks 5-6: continue or adjust based on response.

Monitoring:

• Daily subjective journal: energy (1-10 scale), mood, focus, sleep quality, GI symptoms, headaches, any unusual symptoms.
• Weekly review: is there a clear benefit vs. baseline? Any concerning side effects?

What to expect:

• Onset of effect: some users notice subtle mood/energy changes within 1-3 days; others report gradual improvement over 1-2 weeks.
• Typical subjective report: mild to moderate improvement in mental clarity, motivation, and fatigue resistance. Occasional users describe more pronounced effects ("lifting of a fog"); others report minimal change.
• No "stimulant kick" — sulbutiamine does not produce acute alertness like caffeine or modafinil. Expectations should be calibrated accordingly.

Cycling considerations: many users find that sulbutiamine's subjective effects diminish over 3-6 weeks of daily use (apparent tolerance). Common cycling strategies:

• 5 days on, 2 days off (weekends).
• 2-4 weeks on, 1 week off.
• Intermittent use ("as needed" 2-3 times per week).

No controlled data support one cycling approach over another. Start with continuous daily dosing for 4 weeks to assess, then consider cycling if tolerance appears.

Stopping criteria:

• Persistent headache, GI upset, or other significant side effects.
• Psychiatric destabilisation (increased anxiety, agitation, insomnia, mood changes).
• No perceived benefit after 4 weeks of continuous use — sulbutiamine is unlikely to be helpful for you.

After the starter protocol: if tolerated and beneficial, progression to the intermediate protocol (higher doses and longer durations) is reasonable. If ineffective or tolerance is a problem, sulbutiamine is either not your compound or requires cycling to maintain benefit.

Intermediate protocol (users with confirmed tolerance and benefit on the starter): 400-600 mg/day split into 2-3 doses, with structured cycling.

This protocol matches the French clinical dosing used in asthenia trials (Arcalion 400-600 mg/day). It is for users who have completed the starter protocol, confirmed tolerance, and want to explore the full therapeutic dose range.

Dosing options:

• 400 mg/day option: 200 mg morning + 200 mg early afternoon.
• 600 mg/day option: 200 mg morning + 200 mg late morning + 200 mg early afternoon; OR 300 mg morning + 300 mg early afternoon.
• Choline co-administration: alpha-GPC 600 mg/day OR CDP-choline 500 mg/day, split to align with sulbutiamine doses.

Cycling (strongly recommended at intermediate doses):

• 4 weeks on, 1 week off — allows reassessment of tolerance and response.
• Alternatively: 5 days on, 2 days off weekly cycling.
• The rationale for cycling is that many users report diminishing subjective effects with chronic daily dosing; periodic breaks may help preserve responsiveness.

Monitoring at intermediate doses:

• Daily subjective journal (same as starter).
• Monthly review: maintained benefit? Side effects emerging? Need for dose or cycling adjustment?
• At the end of each cycle (month): consider whether continuing is worthwhile. Signals to continue: clear benefit that returns with use, manageable side effects, fits into overall lifestyle. Signals to reconsider: no benefit, escalating side effects, psychological dependence.

Stacking options at intermediate (one at a time, not all at once):

• Add noopept 10-20 mg/day for users seeking additional cognitive support.
• Add piracetam 1,600-4,800 mg/day for users preferring the racetam family.
• Add modafinil 100-200 mg/day (prescription only) for users who also need wakefulness enhancement.
• Add l-tyrosine 500-1500 mg/day for users wanting additional dopaminergic support, particularly for acute stress or high cognitive demand periods.

Contexts where the intermediate dose may be appropriate:

• Persistent fatigue despite reasonable lifestyle and evaluated medical factors.
• Asthenia in the context of chronic medical conditions (under physician guidance).
• Post-infectious fatigue (e.g., post-COVID fatigue, post-viral syndromes) where preliminary data suggest potential benefit.
• Occupational or seasonal periods of high cognitive demand where short-term fatigue support is desired.

Red flags at intermediate doses:

• Escalating psychiatric symptoms (anxiety, mood changes, sleep disruption).
• Need to keep increasing doses to achieve the same effect — classic tolerance pattern; time to cycle off.
• Persistent GI, cardiovascular, or other physical symptoms.
• Psychological dependence or feeling you cannot function without it — a sign the underlying fatigue needs different evaluation.

Long-term use considerations:

• French clinical practice supports chronic daily use of 400-600 mg/day in patients with ongoing asthenia, under physician supervision.
• Community practice typically favours cycling over continuous dosing.
• Periodic (every 3-6 months) comprehensive reassessment is reasonable — is the compound still useful? Are there new medical factors to evaluate? Does the overall program still make sense?

Stopping strategy:

• If stopping after extended use, consider a brief taper (halving the dose for 3-5 days) rather than abrupt discontinuation to minimise any rebound fatigue.
• Expect some return of baseline fatigue over days to weeks after discontinuation.

Advanced protocol (experienced long-term users with established sulbutiamine response): structured long-cycle regimens up to 800 mg/day, with comprehensive stacking and rigorous self-monitoring.

This protocol is for users with extensive sulbutiamine experience, established patterns of benefit and tolerance, and realistic understanding that doses above the French approved range are not evidence-based.

Dosing options:

• 600 mg/day (approved French upper range): 300 mg morning + 300 mg early afternoon.
• 800 mg/day (above approved range, community-experimental): 400 mg morning + 400 mg early afternoon; OR 300 + 300 + 200 mg across the day.
• Doses above 800 mg/day have no clear rationale from clinical or mechanism data and are not recommended.

Comprehensive advanced stack (illustrative, not endorsed — each component has independent risk-benefit considerations):

• Sulbutiamine 600-800 mg/day in split doses.
• Alpha-GPC 600-900 mg/day OR CDP-choline 500-750 mg/day.
• Noopept 20-30 mg/day in split doses.
• Modafinil 100-200 mg/day 3-5 days/week (prescription required).
• L-tyrosine 1-2 g/day during high-demand periods.
• Basic B-complex vitamin supplement.
• Plus comprehensive lifestyle foundation.

Advanced cycling:

• 8 weeks on, 2 weeks off for stable long-term use.
• Aggressive cycling (5 days on, 2 days off each week) for tolerance prevention.
• Pulsed cycling (2 weeks on at higher dose, 2 weeks off entirely) for users who prefer distinct "on" and "off" periods.

Monitoring at advanced doses:

• Annual comprehensive labs: CBC, CMP, liver function, lipid panel, HbA1c, TSH, vitamin D, B12, ferritin, hs-CRP.
• Every 3 months: subjective comprehensive review with a primary care physician aware of the program.
• Daily journal with structured weekly review.
• Periodic (every 6-12 months) consideration of whether the program is worth continuing at current complexity.

Risks of the advanced approach:

• Tolerance/diminishing returns. Higher doses do not always produce better effects; sometimes they accelerate tolerance.
• Polypharmacy. Stacking multiple compounds makes attribution impossible and increases interaction risk.
• Psychological dependence. The pattern of "I can't function without my stack" is a red flag — the goal is to optimise baseline function, not to create dependency on compounds.
• Opportunity cost. Time, money, and attention spent on stack optimisation is time not spent on other life improvements (career, relationships, physical training, creative work).
• Missed underlying pathology. Persistent need for escalating stimulant/fatigue-support stacks may mask genuine underlying medical issues (thyroid disease, depression, sleep disorders, autoimmune conditions).

Exit strategy and periodic re-evaluation:

• Every 6 months, conduct a structured stack review: what is each component contributing? What would removing one or more components produce? What lifestyle factors could replace pharmacological support?
• Consider periodic full-stack breaks (2-4 weeks off all non-essential compounds) to reset baseline and reassess what is truly needed.
• Aim for the simplest stack that produces the desired result — "add until it works, then subtract until it just works" is a reasonable philosophy.

Advanced users' honest check-in: if you are at 800 mg/day sulbutiamine plus multiple other nootropics and still battling fatigue, the answer is probably not "more compounds." Consider: sleep assessment (polysomnography if suspicion of sleep apnoea), comprehensive psychiatric evaluation, endocrine workup, cardiovascular assessment, and lifestyle factors including exercise capacity and stress load. No stack compensates for foundational deficits.